文献速递肺外科

非小细胞肺癌患者的袖状肺叶切除术:欧洲胸外科医师学会数据库2021年报告

Sleeve lobectomy in patients with non-small-cell lung cancer: a report from the European Society of Thoracic Surgery database 2021.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

该研究基于欧洲胸外科医师学会数据库2007至2021年数据,回顾了1652例接受袖状肺叶或双肺叶切除术的非小细胞肺癌患者。结果显示整体并发症发生率为40.6%,30天死亡率为2.2%,支气管吻合口并发症发生率为1.8%。与开胸手术相比,电视辅助胸腔镜手术与更低的整体并发症发生率和更短住院时间相关。

要点

  • 袖状肺叶切除术在1652例患者中30天死亡率为2.2%,支气管吻合口并发症发生率为1.8%。
  • 电视辅助胸腔镜手术较开胸手术整体并发症发生率更低(30.4% vs 41.7%),住院时间更短(中位5天 vs 8天)。
  • 新辅助治疗未增加心肺并发症风险(OR:1.05;P=0.664)。

核心结论

  • 新辅助治疗后可行袖状肺叶切除术,电视辅助胸腔镜手术可缩短住院时间并降低并发症发生率。

研究设计与样本

  • 基于欧洲胸外科医师学会数据库2007至2021年数据的回顾性分析,纳入接受袖状肺叶切除术或双肺叶切除术的患者1652例,中位年龄63岁,女性446例,男性1206例。

主要发现

  • 袖状肺叶切除术1536例,双肺叶切除术116例;开胸手术1491例(90.2%),电视辅助胸腔镜手术161例(9.8%),中转开胸率21.1%(34例)。
  • 接受新辅助治疗的患者398例(24.1%)。
  • 整体并发症发生率为40.6%,30天死亡率为2.2%。
  • 支气管吻合口并发症发生于29例(1.8%),其中保守治疗6例(20.7%),手术治疗23例(79.3%)。
  • 多因素分析显示,心肺并发症风险升高的相关因素为体重指数<20(OR:2.26;P<0.001)和双肺叶切除术(OR:2.28;P<0.001);年龄<60岁(OR:0.71;P=0.013)、女性(OR:0.54;P<0.001)和电视辅助胸腔镜手术(OR:0.64;P<0.001)与风险降低相关;新辅助治疗与心肺并发症风险增加无关(OR:1.05;P=0.664)。

临床怎么用

  • 对于中心型肺癌,袖状肺叶切除术可安全用于新辅助治疗后的患者;电视辅助胸腔镜手术与更短的住院时间和更低的并发症发生率相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: For centrally located lung tumours, sleeve lobectomy is preferred over pneumectomy. We report on the surgical practices and perioperative outcomes of sleeve resections based on data from the European Society of Thoracic Surgeons database. METHODS: We retrieved data of patients undergoing sleeve lobectomy or bilobectomy from 2007 to 2021. We evaluated baseline characteristics, surgical approach, neoadjuvant treatments, morbidity and postoperative outcomes of open and video-assisted thoracoscopic surgery (VATS) procedures. RESULTS: In total, 1652 patients (median age: 63 years; females/males: 446/1206) underwent sleeve lobectomy (n = 1536) or bilobectomy (n = 116) by open thoracotomy (n = 1491; 90.2%) or VATS (n = 161; 9.8%) with a thoracotomy conversion rate of 21.1% (n = 34); 398 (24.1%) patients received neoadjuvant treatment. Overall morbidity and 30-day mortality were 40.6% and 2.2%, respectively. Bronchial anastomotic complications occurred in 29 patients (1.8%) with conservative treatment in 6 cases (20.7%) and operative management in 23 (79.3%). On multivariable analysis, factors related to the elevated risk of cardiopulmonary complications were body mass index < 20 [odds ratio (OR): 2.26; P < 0.001] and bilobectomy (OR : 2.28, P < 0.001). Age <60 years (OR: 0.71, P = 0.013), female sex (OR: 0.54, P < 0.001) and VATS (0.64, P < 0.001) were associated with decreased risk. Neoadjuvant treatment was not associated with increased risks of cardiopulmonary complications (OR: 1.05; P = 0.664). Compared to open thoracotomy, VATS was associated with significantly decreased overall morbidity (30.4% vs 41.7%, P = 0.006) and length of stay (median: 5 days vs 8 days; P < 0.001). CONCLUSIONS: Sleeve lobectomies can be safely performed after neoadjuvant treatment. The VATS approach fosters shorter length of stay and decreased morbidity.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Gonzalez M, Chriqui LE, Décaluwé H, et al. Sleeve lobectomy in patients with non-small-cell lung cancer: a report from the European Society of Thoracic Surgery database 2021. Eur J Cardiothorac Surg. 2022. PMID: 36346188. doi:10.1093/ejcts/ezac502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。